We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

25 Jun 2026 - 27 Jun 2026
02 Jul 2026 - 04 Jul 2026
08 Jul 2026 - 10 Jul 2026

Robotic Microsurgery System Gains CE Mark for Clinical Use in Europe

By HospiMedica International staff writers
Posted on 12 May 2026

Microsure (Eindhoven, The Netherlands) announced on May 7, 2026 that its MUSA-3 system received CE mark approval, enabling clinical use in Europe. More...

The milestone marks the company’s transition from product development to a clinical medical device business focused on evidence generation and adoption. Microsure develops high‑precision, robot‑assisted systems for microsurgery.

MUSA-3 is designed to assist surgeons during open super‑microsurgical procedures by downscaling and stabilizing hand movements. The system is intended to support super‑micro‑anastomosis on small anatomical structures such as lymphatic ducts, blood vessels, and nerves. Stated applications include free flap surgery, lymphatic surgery, and peripheral nerve surgery.

With the CE mark secured, the company will now focus on generating clinical evidence at leading European centers, strengthening clinical partnerships, and demonstrating how robotic assistance can support surgeons in super-microsurgical procedures. Looking ahead, the organization aims to advance clinical adoption and build the foundation for broader commercialization.

This next phase is also accompanied by a leadership transition intended to support clinical execution. The appointment of Alex Joseph as CEO reflects that shift. Having played a central role in the development of MUSA-3, he brings extensive experience in surgical robotics, clinical settings, and regulated medical device development.

“As I step into the role of CEO, Microsure is entering a new phase. With the CE mark now achieved, our focus is on generating clinical evidence and demonstrating the value of our technology in practice,” said Alex Joseph, Chief Executive Officer, Microsure.

Related Links
Microsure


Gold Member
Neonatal Heel Incision Device
Tenderfoot
Gold Member
12-Channel ECG
CM1200B
Medical Adhesive
MED 5570U
Vessel Sealing Instrument
ERGOseal
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: A simple sensor placed on the infant’s forehead provides crucial information about cerebral blood flow and the amount of oxygen reaching the brain, as well as the amount that is extracted and consumed (Photo courtesy of Université de Montréal)

Optical Brain Monitoring Predicts Neurodevelopmental Outcomes in Preterm Infants

Premature birth, defined as delivery before 37 weeks of gestation, increases the risk of language, motor, and cognitive delays, yet many late preterm infants receive limited follow-up. Clinicians currently... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.